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ABSTRACT
Systemic siRNA administration to target and treat glioblastoma, one of the 
most deadly cancers, requires robust and efficient delivery platform without 
immunogenicity. Here we report newly emerged multivalent naked RNA nanoparticle 
(RNP) based on pRNA 3-way-junction (3WJ) from bacteriophage phi29 to target 
glioblastoma cells with folate (FA) ligand and deliver siRNA for gene silencing. 
Systemically injected FA-pRNA-3WJ RNPs successfully targeted and delivered siRNA 
into brain tumor cells in mice, and efficiently reduced luciferase reporter gene 
expression (4-fold lower than control). The FA-pRNA-3WJ RNP also can target human 
patient-derived glioblastoma stem cells, thought to be responsible for tumor initiation 
and deadly recurrence, without accumulation in adjacent normal brain cells, nor other 
major internal organs. This study provides possible application of pRNA-3WJ RNP for 
specific delivery of therapeutics such as siRNA, microRNA and/or chemotherapeutic 
drugs into glioblastoma cells without inflicting collateral damage to healthy tissues.
INTRODUCTION
The most common primary brain tumors in adults 
are glioblastomas, which are also one of the most deadly 
cancers [1]. For glioblastomas, conventional treatment 
involves surgical resection followed by radiation and 
concurrent chemotherapy. Even with this treatment 
regimen, the median survival of patients with glioblastoma 
is less than 15 months. The poor prognosis is primarily 
due to tumor recurrence, which is thought to originate 
from a subset of cancer stem cells that survive the primary 
treatments. Recent studies suggested that glioblastoma 
stem cell survived the therapeutic stresses and become 
more aggressive when they recur, developing resistance 
to the primary chemotherapy. We sought a new strategy 
targeting both brain tumor cells and glioblastoma stem 
cells to treat the primary brain tumor and prevent tumor 
recurrence. RNA nanotechnology has been rapidly 
growing as a new generation platform for biological 
and medical application [2, 3]. As nanotechnology 
rapidly evolves, many attempts have been made to 
deliver small interfering RNA (siRNA) using viruses, 
liposome, lipid, and polymer based nanoparticles [4]. For 
maximal potential, such nanoparticles must be delivered 
systemically and specifically target intracranial tumors 
with minimal toxicity. Recently, it was reported the pRNA 
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three-way junction (pRNA-3WJ) of the bacteriophage 
phi29 DNA packaging motor can be used to fabricate a 
RNA nanoparticle (RNP) with precise control of shape, 
size and stoichiometry [4-10]. Creation of boiling 
resistant RNPs with controllable shapes and defined 
stoichiometry has been recently reported [11]. The pRNA-
3WJ nanoparticles with 2’-Fluoro (2’-F) modifications 
of U and C nucleotides renders the RNPs resistant to 
RNase degradation enhancing their in vivo half-life while 
retaining authentic functions of the incorporated modules 
[7, 12, 13]. Furthermore, the pRNA-3WJ RNPs were 
non-toxic, non-immunogenic, and displayed favorable 
biodistribution and pharmacokinetic profiles in mice 
[14]. These favorable characteristics make this novel 
platform attractive for the systemic delivery of siRNA 
to glioblastoma. One promising ligand for nanoparticle 
therapy in glioblastoma targeting is folate, a natural 
member of the B-vitamin family. Folate is required for 
early neuronal development and differentiation [15]. Its 
transportation across the blood-cerebrospinal fluid barrier 
(BCSF) occurs by the choroid plexus [16]. The choroid 
plexus expresses the largest amount of folate receptor 
(FR) in a body, while no FR expression is detected in 
cerebellum, cerebrum or spinal cord [17, 18]. Since 
folate is an essential component required during DNA 
replication and methylation in highly proliferating cells, 
many cancer cells, such as those of the brain, ovary, lung, 
breast, kidney, endometrium, colon and bone marrow, 
over-express FRs to increase folate uptake [19]. Folic acid 
(FA), a synthetic oxidized form of folate, has been widely 
used as a ligand in various cancer targeting materials [20]. 
Herein, we report a new strategy to target and 
deliver therapeutic siRNA to brain tumors using FA-
conjugated pRNA-3WJ RNP. We first established 
intracranial tumor xenograft models in mice and then 
systemically administered RNPs through the tail vein. 
Based on fluorescence imaging, we demonstrated that 
the pRNA-3WJ RNP efficiently targeted and internalized 
into brain tumor cells through FR-mediated endocytosis 
with little or no accumulation in adjacent healthy brain 
cells. Gene silencing by the RNPs was also demonstrated 
within the luciferase gene expressing brain tumors. More 
importantly, pRNA-3WJ RNPs were also capable of 
targeting brain tumor stem cells derived from a human 
patient. The data demonstrate that artificially engineered 
RNPs can specifically target brain tumor cells, including 
glioblastoma stem cells, and deliver functional siRNA 
and possibly even therapeutic microRNAs (miRNAs) 
[21]. The results will pave the way for developing 
multifunctional RNPs for disrupting pathways involved 
in glioblastoma biology.
RESULTS 
This study was to assess application of pRNA-3WJ 
RNP for systemic delivery of therapeutic RNA, such as 
siRNA and miRNA, into brain tumors in a mouse model 
system. For targeted delivery of siRNA into brain tumors, 
a multifunctional RNP was constructed, as previously 
described [7, 12, 13, 22], using a scaffold based on 
pRNA sequences of phi29 bacteriophage with slight 
modifications (see Materials and Methods). Three RNA 
modules individually transcribed in vitro or synthesized 
chemically were mixed at equal molar ratio and formed 
three-branched RNP via one-step self-assembly. Each 
RNA module was designed to carry a functional moiety: 
1) FA as the FR targeting ligand; 2) fluorophore Alexa647 
as the imaging agent; and 3) luciferase siRNA as the 
gene silencing functional moiety or scrambled RNA as a 
negative control (Fig. 1A) [7, 12, 13, 22]. The resulting 
RNP was named FA-pRNA-3WJ-si(luc) RNP. Observation 
of the self-assembled FA-pRNA-3WJ-si(luc) RNP under 
atomic force microscopy (AFM) revealed the formation of 
homogeneous three-branched architectures with 3WJ core 
in the center (Fig. 1B), confirming the previous reports that 
modifications on each RNA module did not abrogate the 
shape-controlled self-assembly to retain the pRNA-3WJ 
core structure essential for homogeneous  RNP formation. 
Dynamic light scattering (DLS) determined average 
hydrodynamic diameters of FA-pRNA-3WJ-si(luc) RNP 
to be 5.2 ± 1.2 nm (Fig. 1C), which was smaller than the 
predicted size (10 × 4 × 2 nm) calculated by RNA folding 
software based on expected duplex helix parameters and 
base pair lengths of the three individual RNA modules. 
The discrepancy between DLS measurement and 
computational prediction implies that each protruded 
branch of FA-pRNA-3WJ-si(luc) RNP was avoided from 
averaging three dimensions due to rapid motion of RNPs 
in solution. Another factor that needs to be addressed for 
successful systemic in vivo application of nanoparticles is 
freedom from aggregation to avoid rapid clearance from 
the body and diminished specific interaction between 
the conjugated ligand and cellular target receptors. 
Aggregation depends largely on the surface charge of 
nanoparticles and the surface of RNA is indeed highly 
charged. Aggregation will also change the surface charge 
proportional to the extent of size increase. To determine 
the aggregation extent, FA-pRNA-3WJ-si(luc) RNP was 
subjected to zeta potential analysis to measure the particle 
surface charge. Zeta potential of FA-pRNA-3WJ-si(luc) 
RNP in DEPC H2O was measured as a single peak at ‒15.8 
± 5.6 mV (Fig. 1D), indicating that most FA-pRNA-3WJ-
si(luc) RNP exist as a single form without aggregation. 
These physical properties favor the FA-pRNA-3WJ-si(luc) 
RNP for systemic in vivo application.
Human glioblastoma cells are known to overexpress 
FR, while normal brain cells show no FR expression 
[17-19]. To determine the specific recognition and 
binding capability of FA-pRNA-3WJ-si(luc) RNP 
towards human glioblastoma cells, firstly association 
of FA-Alexa647-pRNA-3WJ with U87EGFRvIII cell 
was tested in vitro in comparison to FA-free control 
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RNP (Alexa647-pRNA-3WJ). Flow cytometry analysis 
showed a higher association of FA-Alexa647-pRNA-
3WJ with U87EGFRvIII cells (63.1 ± 4.5%) than that of 
Alexa647-pRNA-3WJ (40.3 ± 3.7%) (student t-test, p < 
0.001, n=4) (Fig. 2A). When FRs of U87EGFRvIII cells 
were pre-masked by incubating with 1 mM free-folate for 
1 hr of culture before the RNP binding, the association 
between FA-Alexa647-pRNA-3WJ and U87EGFRvIII 
cells was decreased to an extent similar to the negative 
control Alexa647-pRNA-3WJ (Supplementary Fig. S1), 
indicating that the association between FA-Alexa647-
pRNA-3WJ and U87EGFRvIII cells was FR dependent. 
The FR-mediated specific binding of FA-Alexa647-
pRNA-3WJ to U87EGFRvIII cells was further confirmed 
by visualizing the Alexa647 signal from surface-cultured 
U87EGFRvIII cells treated with FA-Alexa647-pRNA-
3WJ RNP under confocal fluorescence microscope. Higher 
fluorescence intensity of Alexa647 dye was observed from 
U87EGFRvIII cells treated with FA-Alexa647-pRNA-
3WJ than those with control RNP (Alexa647-pRNA-
3WJ) (Fig. 2B). Again, the FA-dependent association of 
FA-Alexa647-pRNA-3WJ RNP was abolished by pre-
treatment of U87EGFRvIII cells with 1 mM free folate 
in culture medium (Fig. 2B). The FR-mediated specific 
association between FA-Alexa647-pRNA-3WJ RNP and 
human glioblastoma cell was also observed with other 
glioblastoma cell lines including T98G (Supplementary 
Fig. S2). Taken together, FA-conjugated pRNA-3WJ RNP 
has the capability to recognize and bind to human brain 
tumor cells through FR.
Next, we tested whether FA-pRNA-3WJ RNP can 
specifically target tumor cells in vivo using an orthotropic 
mouse model of glioblastoma. On the 14th day post 
U87EGFRvIII cell implantation into nude mouse brain, 
Figure 1: Construction and characterization of multi-functional pRNA-3WJ RNP for glioblastoma cell targeting. A, 
Construction map of trivalent FA-Alexa647-pRNA-3WJ-si(Luc) RNP harboring three functionalities: Folate (FA) as a targeting ligand; 
Alexa647 as an imaging module; and luciferase siRNA for gene silencing. B, Atomic force microscopy (AFM) image showing three-
branched triangular structure of self-assembled trivalent FA-pRNA-3WJ-si(Luc) RNP. C, Dynamic light scattering (DLS) data showing 
the size of FA-pRNA-3WJ-si(Luc) RNP. D, Zeta potential of FA-pRNA-3WJ-si(Luc) RNP. The data in C and D were obtained from three 
independent experiments.
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intracranial tumor growth in mice was determined by 
MRI (Fig. 2C, top) and randomly separated into three 
groups for injection of PBS and Alexa647-pRNA-3WJ 
as two negative controls, and FA-Alexa647-pRNA-
3WJ as experimental. Each group of mice (n=4) was 
injected via tail vein (1 mg/kg of RNP in 100 μL of 
PBS). Fifteen hours post injection, the mice brains were 
dissected and subjected to fluorescence imaging to detect 
the Alexa647 signal from RNP. A higher fluorescence 
signal of Alexa647 was observed in the brains of mice 
injected with FA-Alexa647-pRNA-3WJ than that in the 
mice brains injected with control RNP (Alexa647-pRNA-
3WJ) (Fig. 2C). ANOVA analysis on the fluorescence 
intensity from each group (n=4) normalized by their tumor 
volumes (Alexa647 intensity/tumor volume) confirmed the 
significant increase in average fluorescence intensity in 
the mouse brains treated with FA-Alexa647-pRNA-3WJ 
(2.052±0.416, s.e.m.) compared to Alexa647-pRNA-
3WJ (1.014±0.279, s.e.m.) (p=0.019) with respect to PBS 
(1.000±0.298, s.e.m.) (Fig. 2D). The brain tumor region 
was frozen sectioned (10 µm thick) and further examined 
under a fluorescence confocal microscope. It revealed that 
FA-Alexa647-pRNA-3WJ RNP was mostly associated 
with counterstained brain tumor cells (Supplementary Fig. 
S3). These in vivo data strongly indicated that systemically 
injected FA-Alexa647-pRNA-3WJ RNP can travel to 
brain tissue, and successfully recognize and bind human 
glioblastoma cells through FA-FR interaction, rather than 
randomly distribute throughout the entire brain tissues. 
After binding to target glioblastoma cells, RNP 
Figure 2: FA-mediated human glioblastoma cell targeting by FA-Alexa647-pRNA-3WJ RNP in vitro and in vivo. A, 
Flow cytometry analysis for FA-dependent human glioblastoma cell U87EGFRvIII targeting in vitro by FA-Alexa647-pRNA-3WJ RNP. 
Alexa647 signals from U87EGFRvIII cells treated with 200 nM of FA-Alexa647-pRNA-3WJ RNP were compared to control RNP (FA-free 
Alexa647-pRNA-3WJ RNP) normalized to PBS control. Percentage of cell populations were analyzed by student t-test (p < 0.001, n=4). 
B, Immunofluorescence confocal microscopy for FA-dependent human glioblastoma cell U87EGFRvIII targeting in vitro by FA-Alexa647-
pRNA-3WJ RNP (middle) in comparison to control RNP (FA-free Alexa647-pRNA-3WJ) (top) or 1 mM free folate pre-treated cells in 
culture media (bottom). Pseudocolor was used for nucleus (blue), cytoskeleton (green) and Alexa647 (red). C, U87EGFRvIII-induced brain 
tumors in mice targeted by FA-Alexa647-pRNA-3WJ RNP. Tumors were determined by MRI (yellow arrows in top panel) and visualized 
by fluorescence in vivo imaging (bottom panel) after tail vein injection of FA or FA-free Alexa647-pRNA-3WJ RNP. Representative images 
from each group of 4 were displayed. D, ANOVA analysis on fluorescence intensity of Alexa647 normalized by tumor volume (mm3), 
p=0.019 (n=4). 
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needs to internalize to deliver its cargo, siRNA, for 
successful target gene silencing, which is the most critical 
property for any nanoparticle to claim its therapeutic 
application. In order to test whether siRNA-loaded FA-
3WJ RNP can silence the target gene in glioblastoma cells 
in mouse brain after systemic administration, we set up 
a luciferase-based gene expression reporter system by 
implanting luciferase gene-expressing U87EGFRvIII cells 
(U87EGFRvIII-Luc) in mouse brain. For a preliminary 
in vitro test, U87EGFRvIII-Luc cells were incubated for 
72 hrs in culture medium containing a range between 0 
and 400 nM of FA-pRNA-3WJ-si(Luc) or scrambled 
RNA-conjugated control FA-pRNA-3WJ-si(Scrm) 
RNPs without any transfection agent. After 72 hrs, FA-
Figure 3: Gene silencing effect of FA-pRNA-3WJ-si(Luc) RNP in human glioblastoma cells and derived tumor. A, A 
wide range (up to 400nM) of FA-pRNA-3WJ-si(Luc) (closed circles) or FA-pRNA-3WJ-si(Scrm) (negative control, open circles) RNPs 
were incubated with U87EGFRvIII-Luc cells in vitro (n=4). The change of luciferase activity was monitored versus the concentration of 
the RNPs. B, Luciferase gene silencing effect of FA-pRNA-3WJ-si(Luc) in vivo after total of three injections. Luciferase activity change 
by FA-pRNA-3WJ-si(Luc) (closed circles) or FA-pRNA-3WJ-si(Scrm) (open circles) were compared by mean bioluminescence intensity 
(n=5), p=0.007. C, Representative in vivo MRI images for tumor volume and bioluminescence intensity for luciferase activity from both 
FA-pRNA-3WJ-siRNA(Luc) or FA-pRNA-3WJ-si(Scrm) after three injections. D, Tumor volumes calculated from MRI compared to 
scrambled control group at day 13 post-xenograft, p=0.468 (n=5). E, Mean fluorescence intensity divided by tumor volume (mm3) was used 
to normalize the variation among the tested mice, p=0.015 (n=5). All error bars indicate s.e.m., and student t-test was used for statistical 
analysis. 
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pRNA-3WJ-si(Luc) clearly reduced luciferase activity in 
a concentration dependent manner. At 400 nM, average 
luciferase activity in U87EGFRvIII-Luc cells incubated 
with FA-pRNA-3WJ-si(Luc) was decreased about 
five folds (0.214±0.210, s.e.m.) with respect to 0 nM. 
However, FA-pRNA-3WJ-si(Scrm) did not significantly 
reduce luciferase activity in the cells (0.876±0.056, 
s.e.m.) compared to 0 nM. The difference of luciferase 
activity at 400 nM between FA-pRNA-3WJ-si(Luc) and 
FA-pRNA-3WJ-si(Scrm) was statistically significant 
(p=0.006) (Fig. 3A). For in vivo test, intracranial tumor 
in mice was induced by implanting U87EGFRvIII-Luc 
cells. Bioluminescence signal measured from the resulted 
brain tumor is expected to correlate with tumor growth. 
When a group of brain tumor-bearing mice (n=5) were 
systemically injected with FA-pRNA-3WJ-si(Scrm) (1 
mg/kg in 100 μL of PBS) for a total of three times over 
6 days, the luciferase activity rapidly increased as the 
tumor grew indicating no effect of the control RNP on 
luciferase gene expression. However, luciferase activity 
from the group of mice (n=5) injected with FA-pRNA-
3WJ-si(Luc) was observed to increase very slowly over 
time (Fig. 3B). After 3 injections, the luciferase activity 
from the mice injected with FA-pRNA-3WJ-si(Luc) was 
significantly lower (p=0.007) than that from the control 
group mice injected with FA-pRNA-3WJ-si(Scrm). The 
luciferase activity from the tested mice at day 13 post 
tumor implantation was mostly lower than that from the 
mice treated with FA-pRNA-3WJ-si(Scrm) (Fig. 3C). 
However, MRI revealed that the relative tumor size 
between those two groups was statistically insignificant 
(1.160±0.352 mm3, s.e.m. with respect to 1.000±0.300 
mm3 in negative control group) (p=0.468, n=5) (Fig. 3D). 
When their luciferase activity was normalized by the 
tumor volumes, the relatively averaged luciferase activity 
over tumor volumes from the mice treated with FA-pRNA-
3WJ-si(Luc) (0.255±0.040 Luminescence Radiance [p/s/
cm²/sr]/tumor volume [mm3], s.e.m.) was significantly 
lower compared to the control mice group treated with 
FA-pRNA-3WJ-si(Scrm) (1.000±0.410 Luminescence 
Radiance [p/s/cm²/sr]/tumor volume [mm3], s.e.m.) 
(p=0.015, n=5) (Fig. 3E). These data strongly indicated 
that FA-pRNA-3WJ RNP not only specifically targeted 
glioblastoma cells, but also successfully internalized into 
the cells and delivered the cargo siRNA. The delivered 
siRNA, more importantly, remained functionally intact 
for the whole time of systemic delivery, confirming both 
stability and therapeutic efficacy of the FA-pRNA-3WJ 
RNPs. The data successfully demonstrated the therapeutic 
usability as a siRNA delivery system for glioblastoma 
treatment.
In clinical settings, glioblastomas are notorious for 
their frequent recurrence with increased aggressiveness 
after initial therapy, resulting in poor survival rates. It has 
been hypothesized that glioblastoma stem cells tend to 
survive the initial treatment and induce tumor recurrence, 
meaning that any therapeutic strategy lacking the ability to 
kill glioblastoma stem cells would not prevent recurrences 
[23]. The potential of FA-pRNA-3WJ RNPs to target 
glioblastoma stem cells and their derived tumor cells 
was investigated. We used human glioblastoma patient–
derived primary neurosphere cells, named “1123”, which 
has been shown to possess stem cell-like characteristics 
including a high level of CD44 expression, self-renewal 
capability and tumorigenicity when implanted in mouse 
brain [24-26]. First, the CD44+ 1123 cells, maintained 
in serum-free sphere culture medium, were incubated in 
vitro with 200 nM of either FA-Alexa647-pRNA-3WJ or 
Alexa647-pRNA-3WJ RNPs. Flow cytometry analysis 
revealed higher FA-Alexa647-pRNA-3WJ binding to the 
1123 cells than control RNP (Alexa647-pRNA-3WJ) (Fig. 
4A). Compared to PBS-treated 1123 cells, 33.2 ± 0.8% 
of CD44+ 1123 cells were positively associated with FA-
Alexa647-pRNA-3WJ RNP. However, Alexa647-pRNA-
3WJ control RNP was associated with only 12.7 ± 0.4% of 
CD44+ 1123 cells. The difference between FA-Alexa647-
pRNA-3WJ and Alexa647-pRNA-3WJ was statistically 
significant (p<0.0001).
For systemic assessment, a group of mice was then 
implanted with 1123 cells to induce intracranial brain 
tumor. Determined by MRI, mice bearing a similar size 
of brain tumors were then injected with PBS, Alexa647-
pRNA-3WJ or FA-Alexa647-pRNA-3WJ RNPs in 100 μL 
of PBS through the tail vein. Fifteen hours post injection, 
the brains were dissected out and subjected to fluorescence 
imaging. Higher accumulation of FA-Alexa647-pRNA-
3WJ RNP was observed in the tumor region, while less 
accumulation of Alexa647 signal was observed from the 
brains treated with either control RNP (Alexa647-pRNA-
3WJ) or PBS (Fig. 4B). When two different dosages of 
FA-Alexa647-pRNA-3WJ RNPs (20 or 100 μg/mouse) 
were tested in a group of mice bearing small sized 
tumors, fluorescence signals were proportional to the 
amount of RNPs injected (Supplementary Fig. S4). These 
observations suggests that FA-Alexa647-pRNA-3WJ RNP 
can also recognize and target human glioblastoma stem 
cells and their derived tumor cells through FA-FR specific 
interaction. Throughout these studies, a fluorescence signal 
from the groups treated with FA-free 3WJ-pRNA control 
RNP was also observed although the extents were always 
lower than the groups treated with FA-3WJ-pRNA RNP. 
This might be explained by the nature of tumor induced 
from human patient derived stem cell-like glioblastoma 
cells, in which the aggressive hypervasculature leaves a 
large portion of blood vessels as “leaky” as they are poorly 
finished before forming a tight junction of the BBB, also 
called the EPR (enhanced permeability and retention) 
effect [27]. 
To assess the biodistribution profile of the 
pRNA-3WJ RNP throughout the body after systemic 
administration, major internal organs, including heart, 
lung, liver, spleen and kidney, were also collected 
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together with brain and subjected to fluorescence imaging. 
Compared to brain, no significant fluorescence signal was 
detected from the internal organs except kidney (Fig. 
4C). The biodistribution profile of FA-pRNA-3WJ RNP 
after its systemic administration was consistent with the 
previous report [28], in that FA-conjugated drugs that 
failed to target tumor cells are cleared from a mouse 
body through the kidney, reducing the safety concern 
of unbound pRNA-3WJ nanoparticles circulating in the 
blood [7, 12-14]. 
DISCUSSION
For successful clinical application of pRNA-3WJ 
RNP for human glioblastoma detection and treatment, 
it was critical to evaluate its capability to access brain 
tumor cells by discriminating them from adjacent normal 
brain cells, and to have favorable biodistribution. To 
address those two goals, the most critical checkpoints 
deciding the drugability of the pRNA-3WJ nanoparticles, 
we employed an orthotropic intracranial glioblastoma 
model system in mice. According to our observations, it 
was clear that FA-conjugated FA-pRNA-3WJ RNP can 
target human glioblastoma cells through FA-FR specific 
interaction-mediated endocytosis by distinguishing 
glioma cells from adjacent normal brain cells. A series of 
in vitro experiments indicated that such targeting in vivo 
was not obviously a result of non-specific accumulation 
Figure 4: FA-mediated targeting of human glioblastoma patient-derived stem cell and derived brain tumor by FA-
Alexa647-pRNA-3WJ RNPs in animal trials and biodistribution study. A, Flow cytometry analysis for in vitro targeting of 
human glioblastoma patient-derived stem cell, 1123, by FA-Alexa647-pRNA-3WJ or Alexa647-pRNA-3WJ RNP co-treated with CD44-
FITC antibody. PBS and CD44-FITC treated cells were used as gating controls. B, Mouse brain tumor derived from 1123 cells was 
evaluated by MRI for tumor size determination (top). After systemic administration of FA-Alexa647-pRNA-3WJ RNP, FA-dependent 
targeting was visualized by fluorescence in vivo imaging in comparison to FA-free Alexa647-pRNA-3WJ RNP. C, Biodistribution profile 
of FA-Alexa647-pRNA-3WJ RNP was obtained by fluorescence imaging of Alexa647 from major internal organs collected together with 
brain.
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for two reasons: 1) association of FA-pRNA-3WJ RNP 
with glioblastoma cells was ligand-dependent; and 2) 
the association was mediated through FA-FR specific 
interaction, since free folate pre-treatment interfered with 
the specific interaction between FA and FRs on the targeted 
cells. This suggests that FA-pRNA-3WJ RNP can target 
and accumulate in FR+ glioblastoma cells. Taken together 
with the fact that our brain imaging data were collected 15 
hrs post injection of FA-3WJ RNA nanoparticles and the 
luciferase gene silencing effect was seen for days, these 
data suggest that FA-pRNA-3WJ RNP can survive in the 
body by retaining the chemical integrity of cargo siRNA 
until it reaches the brain. Most importantly, the therapeutic 
delivery by the FA-3WJ RNA nanoparticles was clearly 
demonstrated by targeting endogenous luciferase mRNAs 
as a reporter system (Fig. 3). The decreased luciferase 
activity observed from a group of mice injected with 
FA-3WJ-pRNA-si(Luc) RNP clearly answered questions 
towards the capability of the FA-3WJ RNP regarding: 1) 
specific targeting to brain tumor cells; 2) internalization 
into brain tumor cells; and 3) releasing the functional 
moiety (siRNA against luciferase mRNA). In addition, 
the targeting capability of pRNA-3WJ nanoparticles for 
both brain tumor cells and glioblastoma stem cells through 
a FA-FR mediated manner will overcome the weak point 
of conventional brain tumor therapies which largely relies 
on surgical debulking and less-specific toxic drugs with 
radiation. In summary, our current study successfully 
demonstrated the drugability of FA-conjugated pRNA-
3WJ RNP as therapeutic gene delivery for clinical 
applications to meet the urgent need of new strategies 
to target and kill both glioblastoma stem cells and their 
derived tumor cells. Due to the ease and flexibility of 
modification of each RNA module, any drug conjugation 
and siRNA can be loaded to the RNP as therapeutic 
functionalities. Recently, microRNAs have been found to 
involve in pathological process in glioblastoma making 
them as promising therapeutic targets [29-32]. Since 
size and working mechanism of miRNAs are similar to 
those of siRNAs [21], therapeutic miRNAs also can be 
considered to be loaded onto the pRNA-3WJ-RNP.
MATERIALS AND METHODS
Construction of FA-Alexa647-pRNA-3WJ-si(Luc) 
RNP
Multifunctional pRNA-3WJ RNP was prepared 
as previously described [7, 12, 13, 22] with slight 
modifications. In brief, three RNA modules, named 
a3WJ (5’-UUGCCAUGUGUAUGUGGG-3’), b3WJ 
(5’-CCCACAUACUUUGUUGAUCC-3’), and 
c3WJ (5’-GGAUCAAUCAUGGCAA-3’), were 
transcribed in vitro or synthesized chemically using 
2’-F modified nucleotides and purified separately to 
homogeneity. For the current study, each RNA module 
was further modified as following: module a3WJ was 
extended with luciferase siRNA sequences (sense: 
5’-CUUACGCUGAGUACUUCGAUU-3’ and anti-sense: 
5’-UCGAAGUACUCAGCGUAAGUU-3’), or scrambled 
as negative control; module b3WJ was conjugated with 
FA at the 3’ end; and module c3WJ was conjugated with 
fluorophore Alexa647 (Alexa Fluor® 647, Invitrogen) at 
the 3’ end. The three RNA modules were mixed at equal 
molar ratio to form one-step self-assembly. The self-
assembled FA-Alexa647-pRNA-3WJ-si(Luc) RNPs were 
purified from 8 M urea-containing PAGE and frozen at 
-80ºC after reconstituted in PBS. To obtain the designated 
concentration for each experiment, the RNPs were further 
diluted in PBS before use. 
Characterization of self-assembled FA-Alexa647-
pRNA-3WJ-si(Luc) RNP
Three dimensional structure and shape of the 
final form of self-assembled FA-Alexa647-pRNA-3WJ-
si(Luc) RNP was analyzed by atomic force microscopy 
(AFM) imaging as described previously [7, 12, 13, 22]. 
Apparent hydrodynamic sizes and zeta potential of pre-
assembled FA-Alexa647-pRNA-3WJ-si(Luc) RNP (1.5 
µM) in DEPC H2O was measured by Zetasizer nano-ZS 
(Malvern Instrument) at 25°C. The laser wavelength was 
633 nm. The data were obtained from three independent 
measurements.
Human glioblastoma cells and human patient-
derived glioblastoma stem cells
Human glioblastoma cells, U87EGFRvIII and 
U87EGFRvIII-Luc (expressing luciferase reporter gene), 
were obtained from Dr. Webster Cavenee (Ludwig Cancer 
Institute, San Diego, CA). Both cells were maintained 
in DMEM/10% FBS/penicillin/streptomycin. Human 
glioblastoma patient-derived glioblastoma stem cell 
“1123” [24] was cultured in DMEM/F12 (Invitrogen) 
supplemented with B27 (1:50), heparin (5 mg/mL), basic 
FGF (bFGF) (20 ng/mL), and EGF (20 ng/mL). Growth 
factors (bFGF and EGF) were added twice a week.
Intracranial human glioblastoma xenografts from 
human glioblastoma cells and human patient-
derived glioblastoma stem cells
Six weeks old athymic female nu/nu mice (Jackson 
Laboratory, Bar Harbor, ME) were housed and handled in 
accordance with the Subcommittee on Research Animal 
Care of the Ohio State University guidelines approved 
by the Institutional Review Board. All mice were fed 
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folate-free diet (Harlan, Indianapolis, IN) for at least two 
weeks before tumor implantation. Intracranial human 
glioblastoma xenograft tumor was induced by implanting 
human glioblastoma cell U87EGFRvIII or human patient-
derived glioblastoma stem cells (1×105 cells per mouse), 
as described previously [33]. Two weeks post intracranial 
tumor implantation, the location and size of the implanted 
tumors were determined by magnetic resonance imaging 
(MRI). 
Magnetic resonance imaging (MRI) for location 
and size of implanted brain tumor in mice
On the indicated day post-surgery of intracranial 
tumor injection, the location and size of the implanted 
tumors were determined by magnetic resonance imaging 
(MRI). Mouse was anesthetized with 2.5% isoflurane 
mixed with 1 L/min carbogen (95% O2 with 5% CO2), 
then maintained with 1% isoflurane thereafter. Maintaining 
core temperature using a warm water bath, imaging was 
performed using a Bruker Biospin 94/30 magnet (Bruker 
Biospin, Karlsruhe, Germany). Mice were injected with 
Magnevist, gadolinium-based contrast agent (Bayer 
Health Care Pharmaceuticals, Wayne, NJ) by an i.p. 
administration with 0.5 mmol/kg dose, then positioned in 
the magnet. T2-weighted RARE imaging was collected 
using a sequence (TR = 3524 ms, TE = 36 ms, rare factor 
= 8, navgs = 2, FOV=20×20 mm, 0.5 mm slice thickness). 
Region-of-interest (ROI) was manually outlined based on 
contrast in signal intensity between brain and tumor tissue.
Fluorescence confocal microscopy for in vitro and 
in vivo RNP binding 
For the in vitro targeting test of pRNA-3WJ RNP, 2 
× 103 of U87EGFRvIII (malignant human glioblastoma) 
cells in 200 µL were plated in Lab-TekII 8-well chamber 
slide (Nunc, Rochester, NY). The next day, the cells 
were washed with PBS and incubated with 200 nM of 
either FA-Alexa647-pRNA-3WJ RNP or control RNP 
(Alexa647-pRNA-3WJ) in 200 µL of culture media for 
2 hrs at 37°C in a CO2 incubator. To block cellular FRs 
by free folate, PBS-washed cells were pre-treated with 
1 mM free folate in 200 µL of culture media for 1 hr at 
37°C in a CO2 incubator before RNP treatment. After 
washing with PBS, the RNP-treated cells were fixed in 
4% paraformaldehyde (PFA) solution for 2 hrs at 4°C. The 
cytoskeleton of the fixed cells was stained by Alexa Fluor 
488 Phalloidin (Invitrogen, Grand Island, NY) for 30 min 
at room temperature and the nucleus stained with 0.01% 
DAPI solution for 10 min at room temperature. The cells 
were then rinsed with PBS for 3 × 10 min and mounted 
with PermaFluor Aqueous Mounting Medium (Thermo 
Scientific). Fluorescence microscopy was performed using 
Olympus 4-filter-based FluoView FV1000-Filter Confocal 
Microscope System (Olympus Corp.) at the wavelengths 
of 461 nm (for the cell nucleus stained by DAPI), 530 
nm (for the cytoskeleton stained by Alexa Fluor 488 
Phalloidin) and 665 nm (for the Alexa647). Images were 
analyzed by Olympus FluoView Viewer software ver. 4.0 
(Olympus). For in vivo targeting, the brain tumor xenograft 
collected 15 hrs after RNP injection was fixed in 4% PFA 
with 10% sucrose in PBS overnight at 4ºC and embedded 
in Tissue-Tek® O.C.T. compound (Sakura Finetek USA, 
Inc., Torrance, CA) for frozen sectioning (10 µm thick). 
The sectioned samples were mounted by ProLong® 
Gold Antifade Reagent with DAPI (Life Technologies 
Corporation, Carlsbad, CA) overnight. The fluorescent 
images were obtained using FluoView FV1000-Filter 
Confocal Microscope System (Olympus Corp.). 
Flow cytometry for in vitro RNP binding
Flow cytometry analysis was performed for in 
vitro targeting by pRNA-3WJ RNP in malignant human 
glioblastoma (U87EGFRvIII) and glioblastoma stem 
cells (1123). The cells were plated in 6-well plate one day 
before RNP binding. After washing with PBS, the cells 
were incubated with 200 nM of either FA-Alexa647-
pRNA-3WJ RNP or Alexa647-pRNA-3WJ RNP in 200 
µL of culture media for 2 hrs at 37°C in a CO2 incubator. 
For blocking cellular FRs by free folate, the PBS-washed 
cells were pre-treated with 1 mM of free folate in 200 µL 
of culture media for 1 hr in 37°C CO2 incubator before 
RNP treatment. After washing with PBS, the cells were 
harvested by trypsinization and fixed in 4% PFA solution 
for 2 hrs at 4°C. The cells were washed with PBS for 
3 times at room temperature, then subjected to Flow 
Cytometry analysis using BD FACS Aria-III Cell Sorter. 
The data were analyzed by FlowJo 7.6.1 software. 
Systemic injection of RNPs to intracranial human 
glioblastoma xenograft tumor bearing mice
Based on the MRI evaluation taken one day before 
RNP injection, a group of mice bearing similarly sized 
tumors at similar location was selected for systemic 
injection of RNPs. Designated amount of RNPs (1 mg/kg 
of mouse body weight) prepared in 100 µL of PBS were 
injected through mouse tail vein. After 15 hrs of RNP 
injection, the brains were dissected out and subjected to 
fluorescence imaging. Tumor volume calculated from 
MRI was also used to normalize fluorescence intensity or 
luciferase activity for each mouse as described below. 
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Fluorescence imaging on human glioblastoma 
xenograft mouse brain tumor 
To investigate the delivery of pRNA-3WJ RNPs in 
vivo, a brain fluorescence imaging study was performed 
after tail vein injection into mice bearing brain tumor. 
The mice were sacrificed by cervical dislocation under 
anesthesia 15 hrs post injection, and brains were dissected 
out of mice. Fluorescence signals were detected from the 
dissected brains using IVIS Lumina Series III Pre-clinical 
In Vivo Imaging System (Perkin Elmer, Waltham, MA) 
with excitation at 640 nm and emission at 660 nm for 2 
min exposure. The fluorescence intensity was expressed 
as Mean Radiant Efficiency [p/s/cm²/sr] / [µW/cm²], then 
normalized by tumor volume (mm3). PBS injected mice 
were used as fluorescence negative control. Major internal 
organs together with brain from the harvested mice were 
collected and subjected to fluorescence imaging for 
assessment of biodistribution profile study.
Bioluminescence whole body imaging for 
luciferase activity
To investigate the siRNA delivery and silencing 
effect of pRNA-3WJ RNPs in vivo, U87EGFRvIII-Luc 
cell-induced brain tumor was prepared into two groups of 
mice (n=5). At 5, 7 and 9 days post-surgery, 1 mg/kg of 
mouse body weight of FA-Alexa647-pRNA-3WJ-si(Luc) 
RNP (or siScrm as negative control) was injected through 
the mouse tail vein in 100 µL of PBS. After each injection, 
mice were subjected to bioluminescence whole body 
imaging to detect the endogenous luciferase expression 
level. Mice were injected with 75 mg/kg Luciferin (Perkin 
Elmer, Waltham, MA), and anesthetized. Bioluminescence 
from the anesthetized mice was detected by ZFOV-24 
zoom lens-installed IVIS Lumina Series III Pre-clinical 
In Vivo Imaging System (Perkin Elmer, Waltham, MA). 
The luminescence intensity was expressed as Averaged 
Radiance [p/s/cm²/sr], then normalized by tumor volume 
(mm3). 
Statistical analysis
All statistical analyses comparing groups of mice 
treated with test and control RNPs were performed by 
either ANOVA or student t-test. p<0.05 was considered 
significant.
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